Skip to main content
. 2018 Jun 25;26(9):445–453. doi: 10.1007/s12471-018-1129-x

Table 1.

Demographic and clinical characteristics per procedural time interval

Characteristics Time interval p-value
First interval
(n = 337)
Second interval
(n = 337)
Third interval
(n = 337)
Age (years)  82 (77–85)  82 (77–85)  81 (77–85)  0.44
Male sex 133 (39.5%) 150 (44.5%) 157 (46.6%)  0.062
Body mass index (kg/m2)  26.7 (24.2–30.6)  26.7 (24.1–30.2)  26.9 (24.0–30.0)  0.57
NYHA class III or IV 249 (73.9%) 239 (70.9%) 234 (69.4%)  0.20
Urgent setting  81 (24.0%)  85 (25.2%)  40 (11.9%) <0.0001
Cardiovascular medical history
– Hypertension 264 (78.3%) 293 (86.9%) 275(81.6%)  0.27
– Atrial fibrillation 120 (35.6%) 144 (42.7%) 139 (41.2%)  0.14
– Valvular surgery  12 (3.6%)  13 (3.9%)  13 (3.9%)  0.84
– Coronary bypass surgery  60 (17.8%)  43 (12.8%)  38 (11.3%)  0.014
– PCI 107 (31.8%)  95 (28.2%)  80 (23.7%)  0.020
– Pacemaker  28 (8.3%)  41 (12.2%)  32 (9.5%)  0.61
– Stroke  32 (9.5%)  45 (13.4%)  34 (10.1%)  0.81
– Peripheral artery disease 106 (31.5%)  96 (28.2%)  90 (26.7%)  0.17
Non-cardiovascular medical history
– COPD 134 (39.8%) 117 (34.7%)  83 (24.6%) <0.0001
– Diabetes mellitus 102 (30.3%) 104 (30.9%) 110 (32.6%)  0.51
– Renal clearance <60 ml/min 145 (43.0%) 145 (43.0%) 133 (39.5%)  0.35
– Liver cirrhosis   6 (1.8%)   9 (2.7%)   3 (0.9%)  0.38
STS-PROM (score)   4.838 (3.315–7.176)   4.833 (3.273–6.868)   4.022 (2.830–5.947)  0.00013
STS-PROM categories <0.0001
– STS-PROM score <4 126 (37.4%) 122 (36.2%) 165 (49.0%)
– STS-PROM score ≥4 <8 142 (42.1%) 156 (46.3%) 137 (40.7%)
– STS-PROM score ≥8  69 (20.5%)  59 (17.5%)  35 (10.4%)
Euroscore I (score)  16.19 (10.34–25.72)  14.70 (10.11–22.22)  12.87 (9.07–20.12) <0.0001
Euroscore II (score)   4.69 (2.82–8.28)   4.31 (2.69–7.44)   3.73 (2.33–6.50) <0.0001
Porcelain aorta  23 (6.8%)  21 (6.2%)  11 (3.3%)  0.042
Hostile chest  26 (7.7%)  25 (7.4%)  24 (7.1%)  0.77
Pre-procedural echocardiography
– LVEF <30%  30/335 (9.0%)  24/337 (7.1%)  26/336 (7.7%)  0.56
– Moderate/severe RVF  18/335 (5.4%)  20/336 (6.0%)  26/335 (7.8%)  0.21
– SPAP >55 mm Hg  45/331 (13.6%)  28/327 (8.6%)  24/327 (7.3%)  0.0070
– Moderate/severe MR  46/336 (13.7%)  39/334 (12.3%)  26/333 (7.8%)  0.016

If data were missing denominators are notated

NYHA New York Heart Association, PCI percutaneous coronary intervention, COPD chronic obstructive pulmonary disease, STS-PROM Society of Thoracic Surgery predicted risk of mortality, LVEF left ventricle ejection fraction, RVF right ventricle failure, SPAP systolic pulmonary artery pressure, MR mitral regurgitation